Cover Image
市場調查報告書

歐洲的孤兒藥市場:開發平台分析

Europe Orphan Drug Pipeline Analysis 2014

出版商 PNS Pharma 商品編碼 302553
出版日期 內容資訊 英文 1430 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
歐洲的孤兒藥市場:開發平台分析 Europe Orphan Drug Pipeline Analysis 2014
出版日期: 2014年01月14日 內容資訊: 英文 1430 Pages
簡介

由罕見疾病分類的疾病,在美國患者數為20萬人以下,在歐洲每1萬人為5人以下。許多治療方法在商業性擴大的現今,對罕見疾病的措施也很缺乏。這樣的情形在這個領域產生出可能性和機會。

本報告提供歐洲中被開發的各種的孤兒藥的詳細的調查,為您概述為以下內容。

第1章 歐洲的孤兒藥市場概要

  • 孤兒藥市場簡介
  • 孤兒藥市場上課題
  • 孤兒藥市場上法規

第2章 孤兒藥臨床開發階段:不明

  • 概要
  • 孤兒藥臨床階段的簡介

第3章 孤兒藥臨床開發階段:臨床試驗前

  • 概要
  • 孤兒藥臨床階段的簡介

第4章 孤兒藥臨床開發階段:臨床試驗

  • 概要
  • 孤兒藥臨床階段的簡介

第5章 孤兒藥臨床開發階段:階段I

  • 概要
  • 孤兒藥臨床階段的簡介

第6章 孤兒藥臨床開發階段:階段I/II

  • 概要
  • 孤兒藥臨床階段的簡介

第7章 孤兒藥臨床開發階段:階段II

  • 概要
  • 孤兒藥臨床階段的簡介

第8章 孤兒藥臨床開發階段:階段II/III

  • 概要
  • 孤兒藥臨床階段的簡介

第9章 孤兒藥臨床開發階段:階段III

  • 概要
  • 孤兒藥臨床階段的簡介

第10章 孤兒藥臨床開發階段:預備登記

  • 概要
  • 孤兒藥臨床階段的簡介

第11章 孤兒藥臨床開發階段:登記完畢

  • 概要
  • 孤兒藥臨床階段的簡介

第12章 上市

  • 概要
  • 已上市孤兒藥簡介

第13章 開發休止或中止的孤兒藥簡介

  • 開發中止的孤兒藥簡介
  • 暫停開發的孤兒藥簡介
目錄

Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. The term "orphan" was associated with these drugs in order to reflect the lack of interest by pharma companies. In the European Union, orphan drugs are known as orphan medicinal products. Many treatments which are commercially available in today's world lack the ability to address most of the rare disease indications. This throws open significant potential and opportunities in the European Union and other regions of the world which are currently untapped.

The rare diseases normally include certain cancers, metabolic conditions, diseases of the nervous system and musculoskeletal disorders, which are extremely life-threatening and impact lesser than 5 people in every 10,000 people. However, as a group, these diseases together could possibly affect close to 30 million people directly or indirectly in Europe. This shows the significant of the need to develop an increasing number of orphan medicinal products in the European region.

"Europe Orphan Drug Pipeline Analysis 2014" by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed in Europe. Research report covers all orphan designated drugs being developed in various clinical phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Europe orphan designated drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "Europe Orphan Drug Pipeline Analysis 2014" research report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • Patent Information
  • Molecular Formula
  • Brand Names
  • Development Agreements
  • ATC Codes

Number of Orphan Designated Drugs in Pipeline by Clinical Phase:

  • Preclinical: 35
  • Clinical: 2
  • Phase-I: 27
  • Phase-I/II: 49
  • Phase-II: 92
  • Phase-II/III: 16
  • Phase-III: 86
  • Preregistration: 24
  • Registered: 21
  • Marketed: 75
  • Unknown: 1
  • No Development Reported: 5
  • Suspended: 6
  • Discontinued: 80
  • Application Withdrawn: 4

Table of Contents

1. Europe Orphan Drug Market Overview

  • 1.1. Orphan Drug Market Intoduction
  • 1.2. Factors Driving Popularity of Orphan Drugs in Europe
  • 1.3. Orphan Drug Market Challenges
  • 1.4. Orphan Drug Market Regulation

2. Orphan Drug Clinical Development Phase: Unknown

  • 2.1. Overview
  • 2.2. Orphan Drug Profile in Clinical Phase

3. Orphan Drug Clinical Development Phase: Preclinical

  • 3.1. Overview
  • 3.2. Orphan Drug Profile in Clinical Phase

4. Orphan Drug Clinical Development Phase: Clinical

  • 4.1. Overview
  • 4.2. Orphan Drug Profile in Clinical Phase

5. Orphan Drug Clinical Development Phase: Phase-I

  • 5.1. Overview
  • 5.2. Orphan Drug Profile in Clinical Phase

6. Orphan Drug Clinical Development Phase: Phase-I/II

  • 6.1. Overview
  • 6.2. Orphan Drug Profile in Clinical Phase

7. Orphan Drug Clinical Development Phase: Phase-II

  • 7.1. Overview
  • 7.2. Orphan Drug Profile in Clinical Phase

8. Orphan Drug Clinical Development Phase: Phase-II/III

  • 8.1. Overview
  • 8.2. Orphan Drug Profile in Clinical Phase

9. Orphan Drug Clinical Development Phase: Phase-III

  • 9.1. Overview
  • 9.2. Orphan Drug Profile in Clinical Phase

10. Orphan Drug Clinical Development Phase: Preregistration

  • 10.1. Overview
  • 10.2. Orphan Drug Profile in Clinical Phase

11. Orphan Drug Clinical Development Phase: Registered

  • 11.1. Overview
  • 11.2. Orphan Drug Profile in Clinical Phase

12. Marketed

  • 12.1. Overview
  • 12.2. Marketed Orphan Drug Profile in Market

13. Suspended & Discontinued Orphan Drug Profiles

  • 13.1. No Development Reported
  • 13.2. Discontinued Orphan Drug Profiles
  • 13.3. Suspended Orphan Drug Profile
  • 13.4. Applications Withdrawl

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top